

World Journal of *Gastroenterology*

World J Gastroenterol 2020 March 14; 26(10): 995-1106



**OPINION REVIEW**

- 995** Global whole family based-*Helicobacter pylori* eradication strategy to prevent its related diseases and gastric cancer
Ding SZ

REVIEW

- 1005** Role of spleen tyrosine kinase in liver diseases
Kurniawan DW, Storm G, Prakash J, Bansal R

MINIREVIEWS

- 1020** Abnormal liver function tests associated with severe rhabdomyolysis
Lim AKH

ORIGINAL ARTICLE**Basic Study**

- 1029** Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism
He M, Wang C, Long XH, Peng JJ, Liu DF, Yang GY, Jensen MD, Zhang LL

Retrospective Cohort Study

- 1042** Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma
Chen MY, Juengpanich S, Hu JH, Topatana W, Cao JS, Tong CH, Lin J, Cai XJ

Retrospective Study

- 1056** Double-balloon endoscopic retrograde cholangiopancreatography for patients who underwent liver operation: A retrospective study
Nishio R, Kawashima H, Nakamura M, Ohno E, Ishikawa T, Yamamura T, Maeda K, Sawada T, Tanaka H, Sakai D, Miyahara R, Ishigami M, Hirooka Y, Fujishiro M
- 1067** Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus
Cao X, Shang QH, Chi XL, Zhang W, Xiao HM, Sun MM, Chen G, An Y, Lv CL, Wang L, Nan YM, Chen CY, Tan ZN, Liu XE, Zhuang H
- 1080** Predictors of outcomes of endoscopic balloon dilatation in strictures after esophageal atresia repair: A retrospective study
Dai DL, Zhang CX, Zou YG, Yang QH, Zou Y, Wen FQ

Prospective Study

- 1088** Technetium-99m-labeled macroaggregated albumin lung perfusion scan for diagnosis of hepatopulmonary syndrome: A prospective study comparing brain uptake and whole-body uptake
Zhao H, Tsao J, Zhang XW, Ma HY, Weng NN, Tang GS, Li X

META-ANALYSIS

- 1098** Is aggressive intravenous fluid resuscitation beneficial in acute pancreatitis? A meta-analysis of randomized control trials and cohort studies
Gad MM, Simons-Linares CR

ABOUT COVER

Associate Editor of *World Journal of Gastroenterology*, Nahum Mendez-Sanchez, FACC, MD, PhD, Doctor, Professor, Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2019 edition of Journal Citation Report® cites the 2018 impact factor for *WJG* as 3.411 (5-year impact factor: 3.579), ranking *WJG* as 35th among 84 journals in gastroenterology and hepatology (quartile in category Q2). CiteScore (2018): 3.43.

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yan-Liang Zhang*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Subrata Ghosh, Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Ze-Mao Gong, Director

PUBLICATION DATE

March 14, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Retrospective Study

Double-balloon endoscopic retrograde cholangiopancreatography for patients who underwent liver operation: A retrospective study

Ryo Nishio, Hiroki Kawashima, Masanao Nakamura, Eizaburo Ohno, Takuya Ishikawa, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Hiroyuki Tanaka, Daisuke Sakai, Ryoji Miyahara, Masatoshi Ishigami, Yoshiki Hirooka, Mitsuhiro Fujishiro

ORCID number: Ryo Nishio (0000-0002-6999-9508); Hiroki Kawashima (0000-0002-3720-781X); Masanao Nakamura (0000-0002-5444-143X); Eizaburo Ohno (0000-0002-7730-4630); Takuya Ishikawa (0000-0001-5814-3555); Takeshi Yamamura (0000-0003-4994-016X); Keiko Maeda (0000-0001-7615-0476); Tsunaki Sawada (0000-0002-4779-9708); Hiroyuki Tanaka (0000-0002-5095-4860); Daisuke Sakai (0000-0001-7300-4473); Ryoji Miyahara (0000-0001-7172-4602); Masatoshi Ishigami (0000-0003-0938-631X); Yoshiki Hirooka (0000-0001-9639-7425); Mitsuhiro Fujishiro (0000-0002-4074-1140).

Author contributions: Nishio R contributed to the conception and design; Nishio R, Kawashima H and Ishikawa T contributed to the analysis and interpretation of the data; Nishio R drafted the article; Kawashima H, Nakamura M, Ohno E, Ishikawa T, Yamamura T, Maeda K, Sawada T, Tanaka H, Sakai D, Miyahara R, Masatoshi Ishigami M and Hirooka Y contributed to critical revision of the article for important intellectual content; Fujishiro M made final approval of the article.

Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Nagoya University Hospital.

Ryo Nishio, Masanao Nakamura, Eizaburo Ohno, Takuya Ishikawa, Hiroyuki Tanaka, Daisuke Sakai, Ryoji Miyahara, Masatoshi Ishigami, Mitsuhiro Fujishiro, Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi Prefecture, Nagoya 4668550, Japan

Hiroki Kawashima, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Department of Endoscopy, Nagoya University Hospital, Aichi Prefecture, Nagoya 4668550, Japan

Yoshiki Hirooka, Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University Hospital, Aichi Prefecture, Toyoake 4701192, Japan

Corresponding author: Hiroki Kawashima, MD, PhD, Associate Professor, Department of Endoscopy, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Aichi Prefecture, Nagoya 4668550, Japan. h-kawa@med.nagoya-u.ac.jp

Abstract

BACKGROUND

Double-balloon endoscopic retrograde cholangiopancreatography (DB-ERC) is widely performed for biliary diseases after reconstruction in gastrointestinal surgery, but there are few reports on DB-ERC after hepatectomy or living donor liver transplantation (LDLT).

AIM

To examine the success rates and safety of DB-ERC after hepatectomy or LDLT.

METHODS

The study was performed retrospectively in 26 patients (45 procedures) who underwent hepatectomy or LDLT (liver operation: LO group) and 40 control patients (59 procedures) who underwent pancreatoduodenectomy (control group). The technical success (endoscope reaching the choledochojunostomy site), diagnostic success (performance of cholangiography), therapeutic success (completed interventions) and overall success rates, insertion and procedure (completion of DB-ERC) time, and adverse events were compared between these groups.

RESULTS

There were no significant differences between LO and control groups in the technical [93.3% (42/45) vs 96.6% (57/59), $P = 0.439$], diagnostic [83.3% (35/42) vs

Informed consent statement: All study participants provided informed written consent prior to study enrollment.

Conflict-of-interest statement: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine is receiving a scholarship donation from FUJIFILM. There are no additional conflict of interest that would pertain to the content of this study.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: November 26, 2019

Peer-review started: November 26, 2019

First decision: January 7, 2020

Revised: January 14, 2020

Accepted: February 15, 2020

Article in press: February 15, 2020

Published online: March 14, 2020

P-Reviewer: Gencdal G, Mohamed SY

S-Editor: Dou Y

L-Editor: A

E-Editor: Ma YJ



83.6% (46/55), $P = 0.968$], therapeutic [97.0% (32/33) vs 97.7% (43/44), $P = 0.836$], and overall [75.6% (34/45) vs 79.7% (47/59), $P = 0.617$] success rates. The median insertion time (22 vs 14 min, $P < 0.001$) and procedure time (43.5 vs 30 min, $P = 0.033$) were significantly longer in the LO group. The incidence of adverse events showed no significant difference [11.1% (5/45) vs 6.8% (4/59), $P = 0.670$].

CONCLUSION

DB-ERC after liver operation is safe and useful but longer time is required, so should be performed with particular care.

Key words: Biliary tract diseases; Double-balloon enteroscopy; Endoscopic retrograde cholangiopancreatography; Hepatectomy; Liver transplantation; Risk management

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The utility of double-balloon endoscopic retrograde cholangiography (DB-ERC) has been widely reported, but the success rates and the examination time varied by reconstruction methods. There are no reports about DB-ERC after hepatectomy, but if the liver was resected, DB-ERC will be more difficult. We compared the elements of DB-ERC after hepatectomy or living donor liver transplantation with control group (after pancreatoduodenectomy). The success rates and incidence of adverse events were equivalent, but the insertion and procedure time were significantly longer. We discuss the difficulty of DB-ERC after hepatectomy.

Citation: Nishio R, Kawashima H, Nakamura M, Ohno E, Ishikawa T, Yamamura T, Maeda K, Sawada T, Tanaka H, Sakai D, Miyahara R, Ishigami M, Hirooka Y, Fujishiro M. Double-balloon endoscopic retrograde cholangiopancreatography for patients who underwent liver operation: A retrospective study. *World J Gastroenterol* 2020; 26(10): 1056-1066

URL: <https://www.wjgnet.com/1007-9327/full/v26/i10/1056.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v26.i10.1056>

INTRODUCTION

It is difficult to perform endoscopic retrograde cholangiopancreatography (ERCP) for biliary diseases in cases with surgical gastrointestinal reconstruction, and if necessary percutaneous transhepatic biliary drainage or reoperation was performed alternatively. In recent years, however, techniques for balloon-assisted ERCP, particularly short-type double-balloon endoscopic retrograde cholangiography (DB-ERC), have been widely reported^[1-4], with utility shown by rates for the endoscope reaching the duodenal papilla or hepaticojejunostomy site of 89%-99.1% and procedural success rates of 93%-100%. But most of reports have discussed Roux-en Y, Billroth II, and pancreatoduodenectomy (including pylorus-preserving and subtotal stomach-preserving procedures) as postoperative reconstruction methods^[5-8].

We have experienced many cases requiring DB-ERC after hepatectomy or living donor liver transplantation (LDLT) performed in our hospital^[9,10]. Reports on DB-ERC for anastomosis site stenosis after LDLT suggest endoscope insertion and procedural success rates of 68%-85% and 78%-88.2%, respectively, which are slightly lower than for DB-ERC in other postoperative reconstruction cases^[11-14]. This may be because endoscope insertion or therapeutic procedures are more difficult due to changes of hepatic volume and afferent loop length after LDLT. On the other hand, there are no reports on the results of DB-ERC in patients after hepatectomy with hepaticojejunostomy.

The aim of this retrospective observational study was to examine the results of DB-ERC in cases of hepatectomy with hepaticojejunostomy or LDLT [hereinafter referred to as liver operation (LO)]. As a control group, we selected patients who underwent pancreatoduodenectomy (including pylorus-preserving and subtotal stomach-preserving procedures) because they had choledochoduodenostomy, as for LO group, but no hepatectomy. The primary endpoint was the success rates of DB-ERC, and the secondary endpoints were the examination time and incidence of adverse events.

MATERIALS AND METHODS

Patients

The patients were 26 patients (45 procedures) in the LO group selected from 161 patients (222 procedures) who underwent DB-ERC from September 2011 to August 2018 at our hospital, and 40 patients (59 procedures) in the control group. Written informed consent was obtained from all patients. DB-ERC was indicated if at least one of the following clinical symptoms or imaging findings was present: (1) Cholangitis; (2) Increase of hepatic enzymes; and (3) Abnormal findings for the biliary duct, such as bile duct stones, dilation of the bile duct and biliary stenosis in computed tomography or magnetic resonance cholangiopancreatography. DB-ERC was not performed for the patients such as (1) a poor general status; (2) a poor status immediately after surgery; (3) clear perforation of the digestive tract; (4) serious cardiovascular or respiratory disease; or (5) no provision of informed consent.

Methods

DB-ERC: A short-type double-balloon endoscope was used in all examinations, with EI-530B endoscope (effective length: 1520 mm, working channel: 2.8 mm, FUJIFILM, Tokyo, Japan) or EI-580BT endoscope (effective length: 1550 mm, working channel: 3.2 mm, FUJIFILM), and TS13101 over-tube (FUJIFILM). CO₂ insufflation was used in all procedures. The examination was performed by experienced endoscopists under conscious sedation with diazepam at 0.02 mg/kg and pentazocine at 7.5 to 15 mg. Sedation was added as needed based on the awake level during the procedure. For patients in whom sufficient sedation could not be ensured with diazepam and pentazocine, dexmedetomidine (loading at 6 µg/kg/h for 10 min, and then maintenance at 0.4 µg/kg/h) was used concomitantly^[15]. After reaching the target site, the body position was changed to dorsal or abdominal to perform ERC.

For insertion to the bile duct, a 3.5 Fr catheter (PR-110Q-1, Olympus Medical Systems, Tokyo, Japan) or 3.9 Fr catheter (TRUEtome™, Boston Scientific, Natick, MA, United States) with a 0.025-inch guidewire (VisiGlide2™, Terumo, Tokyo, Japan or RevoWave-SJ™, Piolax Medical Devices, Kanagawa, Japan) were mainly used. For expansion of the anastomotic region, a balloon catheter (ZARA™, Century Medical, Tokyo, Japan) or EPLBD (CRE™ PRO GI Wireguided, Boston Scientific) were used. Extraction of stones was performed using a basket for stone extraction (FlowerBasket™, Olympus Medical Systems) and a balloon catheter (Multi-3 V™ Plus, Olympus Medical Systems). If biliary stenosis, jaundice, cholangitis, or residual bile duct stones was suspected, a 7 Fr ERBD tube (Zimmon™, Cook Medical, Tokyo, Japan or Medi-Globe Biliary Stent Set, Achenmühle, Germany), 5 Fr or 6 Fr ENBD tube^[16] (SilkyPass™, Boston Scientific or EN-6S-260P32, Gadelius Medical, Kanagawa, Japan) and self-expandable metallic stent (Zilver635™, Cook Medical or Bilerush™, Piolax Medical Devices) were placed. The study was performed after obtaining approval from the ethical committee of our hospital and performed according to the guidelines described in the Helsinki Declaration for biomedical research involving human patients [Clinical trial registration number: UMIN000025631 (UMIN); 2016-0032 (the institutional review board)].

Adverse events: Based on the American Society for Gastrointestinal Endoscopy Guidelines^[17], adverse events were defined as follows: Cholangitis, a fever of $\geq 38^{\circ}\text{C}$ and increased biliary enzymes; pancreatitis, hospitalization prolonged for ≥ 2 d due to abdominal pain with hyperamylasemia; hemorrhage, overt bleeding or hematemesis/melena during procedures or a decrease of Hb 2 or higher; intestinal perforation; and other symptoms with hospitalization prolonged for ≥ 2 d.

Definitions of endpoints: The primary endpoint of this study was the success rate of reaching the hepaticojejunostomy site (*i.e.*, technical success), successful cholangiography after cannulation to the bile duct (*i.e.*, diagnostic success), completed interventions in the bile duct (*i.e.*, therapeutic success), and completed diagnosis and interventions among all procedures (*i.e.*, overall success). The secondary endpoint was the insertion and procedure time, and the incidence of adverse events. Insertion time was defined as the time required to reach the hepaticojejunostomy site, and procedure time as the time from reaching the hepaticojejunostomy site to removal of the endoscope.

Statistical analysis

A χ^2 was used for analyses of the technical, diagnostic, therapeutic and overall success rates, and the incidence of adverse events. A Mann-Whitney *U* test was used for analyses of the insertion and procedure times. All statistical analyses were performed using BellCurve for Excel ver. 2.21 (Social Survey Research Information Co, Ltd.,

Tokyo, Japan).

RESULTS

Patients

Backgrounds of the patients are shown in Table 1, respectively. The 26 LO patients (45 procedures) included 14 patients (18 procedures) who underwent hepatectomy, including right lobectomy (7 patients, 9 procedures), left lobectomy (3 patients, 4 procedures), right trisegmentectomy (1 patients, 2 procedures), and left trisegmentectomy (3 patients, 3 procedures); and 12 patients (27 procedures) who underwent LDLT, including left lobe graft (5 patients, 11 procedures) and right lobe graft (7 patients, 16 procedures). The 40 control patients (59 procedures) underwent pancreatoduodenectomy (9 patients, 13 procedures), pylorus-preserving pancreatoduodenectomy (4 patients, 4 procedures), and stomach-preserving pancreatoduodenectomy (27 patients, 42 procedures).

DB-ERC was underwent in 34 procedures for stenosis of hepaticojejunostomy, 12 for bile duct stones, 9 for cholangitis, 5 for stenosis of biliary duct, and 1 for others (foreign object in bile duct) in the LO group; and in 34 procedures for stenosis of hepaticojejunostomy, 34 for bile duct stones, 13 for cholangitis, 2 for stenosis of biliary duct, and 4 for others (3 for bile duct tumor, 1 for postoperative biliary fistula) in the control group, including duplication.

Success rates

The success rates are shown in Figure 1 and Table 2. There were no significant differences between the LO and control groups for the technical success [93.3% (42/45; 95%CI: 81.7%-98.6%) *vs* 96.6% (57/59; 95%CI: 88.4%-99.1%, $P = 0.439$); diagnostic success [83.3% (35/42; 95%CI: 68.6%-93.0%) *vs* 83.6% (46/55; 95%CI: 71.7%-91.1%, $P = 0.968$); therapeutic success [97.0% (32/33; 95%CI: 84.7%-99.5%) *vs* 97.7% (43/44; 95%CI: 88.2%-99.6%, $P = 0.836$); and overall success [75.6% (34/45; 95%CI: 61.4%-85.8%) *vs* 79.7% (47/59; 95%CI: 67.8%-88.0%), $P = 0.617$].

Two procedures in the control group were not included in the denominator of the diagnostic success because only observation of hepaticojejunostomy was needed. Two procedures in the LO group and 2 in the control group were not included in the denominator of the therapeutic success because the objectives of the examination could be achieved only with confirmation of bile duct images in cholangiography.

Failure in cholangiography was 7 procedures in the LO group and 9 in the control group. As the cause, stenosis of hepaticojejunostomy which could not be passed in 4 procedures, the examinations were abandoned due to difficulty in holding the endoscope at anastomosis sites in 2 procedures, hepaticojejunostomy site could not be found in 1 procedure in the LO group; stenosis of hepaticojejunostomy which could not be passed in 4 procedures, hepaticojejunostomy sites could not be found in 5 procedure in the control group.

Failure in completed interventions was both 1 procedure in the LO group and the control group. As the cause, the difficulty in holding the endoscope at anastomosis site in the LO group; stenosis of hepaticojejunostomy which could not be dilated in the control group.

Examination time

Examination times are shown in Table 3. The median insertion time (22 *vs* 14 min, $P < 0.001$) and procedure time (43.5 *vs* 30 min, $P = 0.033$) were significantly longer in the LO group.

Adverse events

The incidence of adverse events is shown in Table 4. They did not differ significantly between the LO and control groups [11.1% (5/45; 95%CI: 4.8%-23.5%) *vs* 6.8% (4/59; 95%CI: 2.6%-16.1%), $P = 0.670$]. Adverse events included cholangitis in 2, pancreatitis in 1, and bleeding in 2 in the LO group; and cholangitis in 3, and pancreatitis in 1 in the control group. Perforation was not occurred in both groups. All of these adverse events were improved with conservative treatment only.

DISCUSSION

Recently the utility of DB-ERC has been widely reported. Endoscopic treatment for postoperative biliary diseases such as stenosis of hepaticojejunostomy and bile duct stones is important because percutaneous transhepatic biliary drainage and

Table 1 Patients' characteristics

	Liver operation group			Control group			
	26 patients, 45 procedures			40 patients, 59 procedures			
	Hepatectomy	LDLT	Total	PD	PPPD	SSPPD	Total
Sex, male: female, patients	7:7	4:8	11:15	8:1	3:1	15:12	26:14
(male: female, procedures)	(9:9)	(8:19)	(17:28)	(12:1)	(3:1)	(27:15)	(42:17)
Age, median, years old	70	27	61	66	67.5	66.5	67
(IQR)	(66.3-75.8)	(24.5-54.5)	(26-69)	(53-70)	(66.8-68)	(60.5-75)	(61-74)
Indication of surgical gastrointestinal reconstruction, procedures							
Biliary disease (malignant)	14	0	14	2	0	8	10
Biliary disease (benign)	3	15	18	0	0	0	0
Liver disease (malignant)	1	3	4	0	0	0	0
Liver disease (benign)	0	9	9	0	0	0	0
Pancreatic disease (malignant)	0	0	0	8	4	27	39
Pancreatic disease (benign)	0	0	0	0	0	1	1
Gastric/duodenal disease (malignant)	0	0	0	3	0	6	9
Indication of DB-ERC (including duplication), procedures							
Stenosis of hepaticojejunostomy	13	21	34	4	4	26	34
Bile duct stones	6	6	12	10	1	23	34
Cholangitis	4	5	9	3	1	9	13
Stenosis of biliary duct	1	4	5	0	0	2	2
Others	1	0	1	0	0	4	4

LDLT: Living donor liver transplantation; PD: Pancreatoduodenectomy; PPPD: Pylorus-preserving pancreatoduodenectomy; SSPPD: Subtotal stomach-preserving pancreatoduodenectomy; DB-ERC: Double-balloon endoscopic retrograde cholangiopancreatography; IQR: Interquartile range.

reoperation can be avoided. Some reports suggest technical, diagnosis, and therapeutic success rates of $\geq 90\%$ regardless of the reconstruction method. Our success rates were slightly lower in the LO group, but equivalent to reports on DB-ERC for LDLT.

Despite these successes, it is still challenging to perform DB-ERC with surgical gastrointestinal reconstruction due to difficulties with the procedure and development of adverse events. Itokawa *et al*^[18] suggested that DB-ERC is difficult due to postoperative adhesion and bending of the bowel, and Yane *et al*^[19] showed that pancreatic indications, first ERCP attempt and without a transparent hood may be a cause of unsuccessful single-balloon enteroscope-assisted ERCP. When an endoscope is inserted in patients after hepatectomy or LDLT, there is a long distance to the anastomotic site, and also a high level of adhesion due to operative stress, a lower liver volume due to hepatectomy, changes in running of gastrointestinal tract due to successive hepatomegaly, and easy bending upon insertion of the endoscope. These factors increase the difficulty of DB-ERC for LO group compared to that after other postoperative cases. In DB-ERC, it is difficult to align the endoscope in a straight line and view the anastomotic site squarely in many cases, and this might affect the procedure time, as seen in the results of the current study (Figure 2, Table 2). Furthermore, the difficulty of DB-ERC may be different between patients who had right robe and left robe or underwent bisegmentectomy and trisegmentectomy, but there was no significant difference in this study due to the small number.

Many patients also require reexamination, even when procedures are successful. Tomoda *et al*^[13] found a procedural success rate of 82.4% in balloon dilatation for stenosis of hepaticojejunostomy after LDLT, but 50% of these patients developed restenosis within 9.6 months. In a similar study, Kamei *et al*^[20] found that 66.7% of cases developed restenosis.

In our study, the incidence of adverse events was higher than that in past reports, and there were no significant differences in success rates and insertion time between patients with and without adverse events for the technical success [100% (9/9) *vs* 94.7% (90/95), $P = 0.481$]; diagnostic success [88.9% (8/9) *vs* 83.0% (73/88), $P = 0.648$]; therapeutic success [100% (8/8) *vs* 97.1% (67/69), $P = 0.626$]; overall success [88.9% (8/9) *vs* 76.8% (73/95), $P = 0.405$]; and the median insertion time [16 *vs* 18 min, $P = 0.795$], but procedure time was significantly longer in the patients with adverse events




Figure 1 Flowchart of patients' process. Technical success: Endoscope reached the hepaticojejunostomy site; Diagnostic success: Successful cholangiography after cannulation to the bile duct; Therapeutic success: Completed interventions in the bile duct; Overall success: Completed diagnosis and interventions among all cases.

(60 vs 34 min, $P = 0.034$) (Table 5). No major differences in these factors compared to past reports. Therefore, anatomic factors in patients after hepatectomy or LDLT, as mentioned above, and longer procedure time might have caused more adverse events. Hyperamylasemia and pancreatitis after double-balloon endoscope have been reported, and inflated balloon or prolonged mechanical stress on the pancreas may be a cause of pancreatitis^[21,22]. Similar processes might have happened in this study. As in regular ERCP, pancreatography is a risk factor for hyperamylasemia and pancreatitis, and pancreatography was performed in 3 of the 5 control procedures who developed hyperamylasemia or pancreatitis in this study. A long insertion time or pancreatography may cause more intense mechanical stimulation of the pancreas, even when the endoscope does not contact the duodenal papilla. However, only a few studies of adverse events after DB-ERC have been reported, and a further study is required to identify risk factors for adverse events in the future.

In this study, we used two different endoscopes (procedures who underwent DB-ERC by EI-530B were 19 in the LO group and 17 in the control group, and by EI-580BT were 26 in the LO group and 42 in the control group), there were no significant difference in the success rates, procedure times and adverse events between two groups.

The limitations of this study include the retrospective design in a limited number of patients at a single facility; and inclusion patients who underwent DB-ERC twice or more; and the difference of diseases between the two groups; and inclusion patients who underwent DB-ERC with different endoscopes. Further accumulation of patients is required for a future study. Within these limitations, we conclude that DB-ERC is safe and useful for patients who underwent hepatectomy or LDLT, but the success rates may be slightly lower, the insertion and procedures time significantly longer,

Table 2 Technical, diagnostic, therapeutic and overall success rates

	Liver operation group			Control group				<i>P</i> value ¹	Effect size ²
	26 patients, 45 procedures			40 patients, 59 procedures					
	Hepatec-tomy	LDLT	Total	PD	PPPD	SSPPD	Total		
Technical success	16/18	26/27	42/45	13/13	4/4	40/42	57/59	0.439	0.076
Procedures (%)	(88.9)	(96.3)	(93.3)	(100)	(100)	(95.2)	(96.6)		
Diagnostic success	11/16	24/26	35/42	12/12	3/4	31/39	46/55	0.968	0.004
Procedures (%)	(68.8)	(92.3)	(83.3)	(100)	(75.0)	(79.5)	(83.6)		
Therapeutic success	10/10	22/23	32/33	12/12	3/3	28/29	43/44	0.836	0.024
Procedures (%)	(100)	(95.7)	(97.0)	(100)	(100)	(96.6)	(97.7)		
Overall success	11/18	23/27	34/45	13/13	3/4	31/42	47/59	0.617	0.049
Procedures (%)	(61.1)	(85.2)	(75.6)	(100)	(75.0)	(73.8)	(79.7)		

¹ χ^2 (Total of Liver operation group *vs* Control group).

²phi coefficient. LDLT: Living donor liver transplantation; PD: Pancreatoduodenectomy; PPPD: Pylorus-preserving pancreatoduodenectomy; SSPPD: Subtotal stomach-preserving pancreatoduodenectomy; Technical success: Endoscope reached the hepaticojunostomy site; Diagnostic success: Successful cholangiography after cannulation to the bile duct; Therapeutic success: Completed interventions in the bile duct; Overall success: Completed diagnosis and interventions among all procedures.

and the incidence of adverse events slightly higher than those after pancreatoduodenectomy.

In conclusion, DB-ERC is safe and useful for patients who underwent hepatectomy or LDLT, but particular care with the endoscope and obtaining informed consent are essential before DB-ERC is performed.

Table 3 Insertion and procedure time

	Liver operation group			Control group				<i>P</i> value ¹	Effect size ²
	Hepatectomy	LDLT	Total	PD	PPPD	SSPPD	Total		
Insertion time	19.5	24	22	14	26	14	14	< 0.001	0.772
Median, min (IQR)	(14.3-29.3)	(18-41)	(16-40)	(7-20)	(15.5-44.8)	(10.3-21.3)	(10-23)		
Procedure time	45.5	40	43.5	34	18	30	30	0.033	0.444
Median, min (IQR)	(29.8-62.5)	(22.8-60.5)	(28.3-61.5)	(24-45)	(14.5-30.8)	(21.5-43.8)	(21-44)		

¹Mann-Whitney U test (Total of Liver operation group *vs* Control group).²Cohen's *d*. LDLT: Living donor liver transplantation; PD: Pancreatoduodenectomy; PPPD: Pylorus-preserving pancreatoduodenectomy; SSPPD: Subtotal stomach-preserving pancreatoduodenectomy; Insertion time: The time required to reach the hepaticojunostomy site; Procedure time: The time from reaching the hepaticojunostomy site to removal of the endoscope; IQR: Interquartile range.**Table 4 Adverse events**

	Liver operation group			Control group				P value ¹	Effect size ²
	26 patients, 45 procedures			40 patients, 59 procedures					
	Hepatectomy	LDLT	Total	PD	PPPD	SSPPD	Total		
Adverse events	3/18	2/27	5/45	2/13	1/4	1/42	4/59	0.670	0.076
Procedures (%)	(16.7)	(7.4)	(11.1)	(15.4)	(25)	(2.4)	(6.8)		
Cholangitis	2	0	2	2	0	1	3		
Pancreatitis	1	0	1	0	1	0	1		
Bleeding	0	2	2	0	0	0	0		
Perforation	0	0	0	0	0	0	0		

¹ χ^2 (Total of Liver operation group *vs* Control group).²phi coefficient. LDLT: Living donor liver transplantation; PD: Pancreatoduodenectomy; PPPD: Pylorus-preserving pancreatoduodenectomy. SSPPD: Subtotal stomach-preserving pancreatoduodenectomy.**Table 5 Differences of success rates, insertion and procedure time with or without adverse events**

	With adverse events	Without adverse events	<i>P</i> value ¹	Effect size ²
	9 patients, 9 procedures	57 patients, 95 procedures		
Technical success	9/9	90/95	0.481	0.069
Procedures (%)	(100)	(94.7)		
Diagnostic success	8/9	73/88	0.648	0.046
Procedures (%)	(88.9)	(83.0)		
Therapeutic success	8/8	67/69	0.626	0.056
Procedures (%)	(100)	(97.1)		
Overall success	8/9	73/95	0.405	0.082
Procedures (%)	(88.9)	(76.8)		
Insertion time	16	18	0.795	0.093
Median, min (IQR)	(9-25)	(12-28)		
Procedure time	60	34	0.034	0.762
Median, min (IQR)	(46-62)	(21-49)		

¹ χ^2 : success rates; Mann-Whitney U test: Insertion and procedure time.²phi coefficient: success rates; Cohen's *d*: Insertion and procedure time. Technical success: Endoscope reached the hepaticojunostomy site; Diagnostic success: Successful cholangiography after cannulation to the bile duct; Therapeutic success: Completed interventions in the bile duct; Overall success: Completed diagnosis and interventions among all procedures; Insertion time: The time required to reach the hepaticojunostomy site; Procedure time: The time from reaching the hepaticojunostomy site to removal of the endoscope; IQR: Interquartile range.




Figure 2 Endoscopic and fluoroscopic images of double-balloon endoscopic retrograde cholangiography. A: After right hepatic lobectomy; B: After living donor liver transplantation (right lobe graft); C: After pancreatoduodenectomy. These are endoscopic (upper) and fluoroscopic (lower) images of double-balloon endoscopic retrograde cholangiography. Endoscopic image: In A and B, procedures were difficult because the hepaticojunostomy site was located near the edge of the visual field and close to the endoscope. In C, the hepaticojunostomy site was located at the center of the visual field, and the distance from the endoscope was appropriate. Fluoroscopic image: In A and B, the endoscope bowed to the side of the removed liver, but no such bowing is observed in C.

ARTICLE HIGHLIGHTS

Research background

Double-balloon endoscopic retrograde cholangiography (DB-ERC) is widely performed for biliary diseases after reconstruction in gastrointestinal surgery, but the success rates and the examination time varied by reconstruction methods.

Research motivation

There are few reports on DB-ERC after hepatectomy or living donor liver transplantation (LDLT), and we have experienced many cases requiring DB-ERC after hepatectomy or LDLT performed in our hospital.

Research objectives

The objective of this study is to examine the success rates and safety of DB-ERC after hepatectomy or LDLT, and to reveal the inherent difficulties of them.

Research methods

The study was performed retrospectively in patients who underwent DB-ERC after hepatectomy or LDLT [hereinafter referred to as liver operation (LO) group] and control patients after pancreatoduodenectomy (control group). The technical success (endoscope reaching the choledochojunostomy site), diagnostic success (performance of cholangiography), therapeutic success (completed interventions) and overall success rates, insertion and procedure (completion of DB-ERC) time, and adverse events were compared between these groups.

Research results

There were no significant differences between the LO and control groups for the success rates and the incidence of adverse events, but the median insertion time and procedure time were significantly longer in the LO group.

Research conclusions

DB-ERC is safe and useful for patients who underwent hepatectomy or LDLT. Although it may be difficult because of not only gastrointestinal reconstruction, but also lower liver volume: changes in running of gastrointestinal tract due to successive hepatomegaly: and easy bending

upon insertion of the endoscope. So particular care with the endoscope and obtaining informed consent are essential before DB-ERC is performed.

Research perspectives

DB-ERC will be performed safely and easily for patients who underwent any gastrointestinal reconstruction.

REFERENCES

- 1 Shimatani M, Hatanaka H, Kogure H, Tsutsumi K, Kawashima H, Hanada K, Matsuda T, Fujita T, Takaoka M, Yano T, Yamada A, Kato H, Okazaki K, Yamamoto H, Ishikawa H, Sugano K; Japanese DB-ERC Study Group. Diagnostic and Therapeutic Endoscopic Retrograde Cholangiography Using a Short-Type Double-Balloon Endoscope in Patients With Altered Gastrointestinal Anatomy: A Multicenter Prospective Study in Japan. *Am J Gastroenterol* 2016; **111**: 1750-1758 [PMID: 27670601 DOI: 10.1038/ajg.2016.420]
- 2 Skinner M, Popa D, Neumann H, Wilcox CM, Mönkemüller K. ERCP with the overtube-assisted enteroscopy technique: a systematic review. *Endoscopy* 2014; **46**: 560-572 [PMID: 24839188 DOI: 10.1055/s-0034-1365698]
- 3 Katanuma A, Maguchi H, Yane K, Kin T, Ikarashi S, Yamazaki H, Kitagawa K, Koga H, Yokoyama K, Sano I, Nagai K, Takahashi K. [Current advancement of balloon-enteroscopy-assisted ERCP]. *Nihon Shokakibyo Gakkai Zasshi* 2016; **113**: 603-613 [PMID: 27052390 DOI: 10.11405/nissoshio.113.603]
- 4 Shimatani M, Tokuhara M, Kato K, Miyamoto S, Masuda M, Sakao M, Fukata N, Miyoshi H, Ikeura T, Takaoka M, Okazaki K. Utility of newly developed short-type double-balloon endoscopy for endoscopic retrograde cholangiography in postoperative patients. *J Gastroenterol Hepatol* 2017; **32**: 1348-1354 [PMID: 28019036 DOI: 10.1111/jgh.13713]
- 5 Yamauchi H, Kida M, Imaizumi H, Okuwaki K, Miyazawa S, Iwai T, Koizumi W. Innovations and techniques for balloon-enteroscopy-assisted retrograde cholangiopancreatography in patients with altered gastrointestinal anatomy. *World J Gastroenterol* 2015; **21**: 6460-6469 [PMID: 26074685 DOI: 10.3748/wjg.v21.i21.6460]
- 6 Ishii K, Itoi T, Tonozuka R, Itokawa F, Sofuni A, Tsuchiya T, Tsuji S, Ikeuchi N, Kamada K, Umeda J, Tanaka R, Honjo M, Mukai S, Fujita M, Moriyasu F, Baron TH, Gotoda T. Balloon enteroscopy-assisted ERCP in patients with Roux-en-Y gastrectomy and intact papillae (with videos). *Gastrointest Endosc* 2016; **83**: 377-86.e6 [PMID: 26234697 DOI: 10.1016/j.gie.2015.06.020]
- 7 Mizukawa S, Tsutsumi K, Kato H, Muro S, Akimoto Y, Uchida D, Matsumoto K, Tomoda T, Horiguchi S, Okada H. Endoscopic balloon dilatation for benign hepaticojejunostomy anastomotic stricture using short double-balloon enteroscopy in patients with a prior Whipple's procedure: a retrospective study. *BMC Gastroenterol* 2018; **18**: 14 [PMID: 29347923 DOI: 10.1186/s12876-018-0742-x]
- 8 Kawashima H, Nakamura M, Ohno E, Goto H, Hirooka Y. Impact of instrument channel diameter on therapeutic endoscopic retrograde cholangiography using balloon-assisted enteroscopy. *Dig Endosc* 2014; **26** Suppl 2: 127-129 [PMID: 24750162 DOI: 10.1111/den.12262]
- 9 Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. *Ann Surg* 2013; **258**: 129-140 [PMID: 23059502 DOI: 10.1097/SLA.0b013e3182708b57]
- 10 Kamei H, Imai H, Onishi Y, Ishihara M, Nakamura M, Kawashima H, Ishigami M, Ito A, Ohmiya N, Hirooka Y, Goto H, Ogura Y. Considerable Risk of Restenosis After Endoscopic Treatment for Hepaticojejunostomy Stricture After Living-Donor Liver Transplantation. *Transplant Proc* 2015; **47**: 2493-2498 [PMID: 26518958 DOI: 10.1016/j.transproceed.2015.09.015]
- 11 Chua TJ, Kaffes AJ. Balloon-assisted enteroscopy in patients with surgically altered anatomy: a liver transplant center experience (with video). *Gastrointest Endosc* 2012; **76**: 887-891 [PMID: 22840290 DOI: 10.1016/j.gie.2012.05.019]
- 12 Sanada Y, Mizuta K, Yano T, Hatanaka W, Okada N, Wakiya T, Umehara M, Egami S, Urahashi T, Hishikawa S, Fujiwara T, Sakuma Y, Hyodo M, Yamamoto H, Yasuda Y, Kawarasaki H. Double-balloon enteroscopy for bilioenteric anastomotic stricture after pediatric living donor liver transplantation. *Transpl Int* 2011; **24**: 85-90 [PMID: 20738835 DOI: 10.1111/j.1432-2277.2010.01156.x]
- 13 Tomoda T, Tsutsumi K, Kato H, Mizukawa S, Yabe S, Akimoto Y, Seki H, Uchida D, Matsumoto K, Yamamoto N, Horiguchi S, Okada H. Outcomes of management for biliary stricture after living donor liver transplantation with hepaticojejunostomy using short-type double-balloon enteroscopy. *Surg Endosc* 2016; **30**: 5338-5344 [PMID: 27059976 DOI: 10.1007/s00464-016-4886-x]
- 14 Tsujino T, Isayama H, Kogure H, Sato T, Nakai Y, Koike K. Endoscopic management of biliary strictures after living donor liver transplantation. *Clin J Gastroenterol* 2017; **10**: 297-311 [PMID: 28600688 DOI: 10.1007/s12328-017-0754-z]
- 15 Oshima H, Nakamura M, Watanabe O, Yamamura T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Goto H, Hirooka Y. Dexmedetomidine provides less body motion and respiratory depression during sedation in double-balloon enteroscopy than midazolam. *SAGE Open Med* 2017; **5**: 2050312117729920 [PMID: 28904794 DOI: 10.1177/2050312117729920]
- 16 Kawashima H, Hirooka Y, Ohno E, Ishikawa T, Miyahara R, Watanabe O, Hayashi K, Ishigami M, Hashimoto S, Ebata T, Nagino M, Goto H. Effectiveness of a modified 6-Fr endoscopic nasobiliary drainage catheter for patients with preoperative perihilar cholangiocarcinoma. *Endosc Int Open* 2018; **6**: E1020-E1030 [PMID: 30105289 DOI: 10.1055/a-0614-2202]
- 17 Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. *Gastrointest Endosc* 2010; **71**: 446-454 [PMID: 20189503 DOI: 10.1016/j.gie.2009.10.027]
- 18 Itokawa F, Itoi T, Ishii K, Sofuni A, Moriyasu F. Single- and double-balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y plus hepaticojejunostomy anastomosis and Whipple resection. *Dig Endosc* 2014; **26** Suppl 2: 136-143 [PMID: 24750164 DOI: 10.1111/den.12254]
- 19 Yane K, Katanuma A, Maguchi H, Takahashi K, Kin T, Ikarashi S, Sano I, Yamazaki H, Kitagawa K,

- Yokoyama K, Koga H, Nagai K, Nojima M. Short-type single-balloon enteroscope-assisted ERCP in postsurgical altered anatomy: potential factors affecting procedural failure. *Endoscopy* 2017; **49**: 69-74 [PMID: [27760436](#) DOI: [10.1055/s-0042-118301](#)]
- 20 **Kamei H**, Al-Basheer M, Shum J, Bloch M, Wall W, Quan D. Comparison of short- and long-term outcomes after early versus late liver retransplantation: a single-center experience. *J Surg Res* 2013; **185**: 877-882 [PMID: [23953787](#) DOI: [10.1016/j.jss.2013.07.013](#)]
- 21 **Itaba S**, Nakamura K, Aso A, Tokunaga S, Akiho H, Ihara E, Iboshi Y, Iwasa T, Akahoshi K, Ito T, Takayanagi R. Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach. *Dig Endosc* 2013; **25**: 421-427 [PMID: [23368820](#) DOI: [10.1111/den.12014](#)]
- 22 **Tsujikawa T**, Bamba S, Inatomi O, Hasegawa H, Ban H, Nishida A, Imaeda H, Itoh A, Saotome T, Sasaki M, Andoh A. Factors affecting pancreatic hyperamylasemia in patients undergoing peroral single-balloon enteroscopy. *Dig Endosc* 2015; **27**: 674-678 [PMID: [25630832](#) DOI: [10.1111/den.12449](#)]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

